About us
- >
- About us >
- Information >
- Announcement
2023-05-31
The Phase III clinical trial of ENERGI-F703 diabetic foot ulcer topical gel has officially commenced, with the enrollment it's first patient.
We are thrilled to announce that on May 31, 2023, our company received notification from the Contract Research Organization (CRO) that the Phase III clinical trial of our investigational new drug, ENERGI-F703 diabetic foot ulcer topical gel, has been officially initiated, and we have successfully enrolled the first patient.